Maky  Zanganeh net worth and biography

Maky Zanganeh Biography and Net Worth

Dr. Maky Zanganeh has served as Summit’s Chief Operating Officer and has been a member of the Board of Directors since November 2020.

She has more than 15 years of management, corporate, clinical, and business experience in the pharmaceutical, medical device, and technology industries.

Most recently, Dr. Zanganeh is the Founder & CEO of Maky Zanganeh and Associates (“MZA”), which provides consulting services to businesses in product development, research, and transactions.

Prior to starting and leading MZA, Dr. Zanganeh held multiple leadership positions at Pharmacyclics, Inc., from 2008 to 2015, culminating in her role as Chief Operating Officer, where she oversaw all clinical, research, commercial, and business-related matters. Dr. Zanganeh played a key role both in the multimillion-dollar collaboration and license deal for ibrutinib (later marketed as IMBRUVICA®) with Janssen Biotech, Inc. in 2011, and the subsequent sale of Pharmacyclics to AbbVie Inc. in 2015.  The acquisition of Pharmacyclics by AbbVie remains one of the largest transactions to have occurred in the pharmaceutical and biotechnology industries.

Previously, she held senior positions of increasing responsibility within companies such as Robert Duggan & Associates, a private investment firm, and Computer Motion, Inc., a pioneer in robotic surgery.

Dr. Zanganeh earned FierceBiotech’s “Top Women in Biotech” award in 2013.  She received her DDS from Louis Pasteur University (France) and her MBA from Schiller International University (France).

Beyond Summit, Dr. Zanganeh is currently a board member for Pulse BioSciences, Inc. and RenovoRx, Inc.

What is Maky Zanganeh's net worth?

The estimated net worth of Maky Zanganeh is at least $6.86 million as of June 23rd, 2020. Dr. Zanganeh owns 352,500 shares of Summit Therapeutics stock worth more than $6,863,175 as of November 14th. This net worth evaluation does not reflect any other investments that Dr. Zanganeh may own. Learn More about Maky Zanganeh's net worth.

How do I contact Maky Zanganeh?

The corporate mailing address for Dr. Zanganeh and other Summit Therapeutics executives is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. Summit Therapeutics can also be reached via phone at 650-460-8308 and via email at [email protected]. Learn More on Maky Zanganeh's contact information.

Has Maky Zanganeh been buying or selling shares of Summit Therapeutics?

Maky Zanganeh has not been actively trading shares of Summit Therapeutics within the last three months. Most recently, on Wednesday, May 12th, Maky Zanganeh bought 389,077 shares of Summit Therapeutics stock. The stock was acquired at an average cost of $5.24 per share, with a total value of $2,038,763.48. Learn More on Maky Zanganeh's trading history.

Who are Summit Therapeutics' active insiders?

Summit Therapeutics' insider roster includes Ankur Dhingra (CFO), Robert Duggan (CEO), Mahkam Zanganeh (CEO), and Maky Zanganeh (COO). Learn More on Summit Therapeutics' active insiders.

Are insiders buying or selling shares of Summit Therapeutics?

In the last year, Summit Therapeutics insiders bought shares 4 times. They purchased a total of 155,400 shares worth more than $542,118.00. The most recent insider tranaction occured on March, 26th when CEO Mahkam Zanganeh bought 30,000 shares worth more than $112,500.00. Insiders at Summit Therapeutics own 88.3% of the company. Learn More about insider trades at Summit Therapeutics.

Information on this page was last updated on 3/26/2024.

Maky Zanganeh Insider Trading History at Summit Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2021Buy389,077$5.24$2,038,763.48View SEC Filing Icon  
See Full Table

Maky Zanganeh Buying and Selling Activity at Summit Therapeutics

This chart shows Maky Zanganeh's buying and selling at Summit Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Summit Therapeutics Company Overview

Summit Therapeutics logo
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $19.47
Low: $19.43
High: $21.74

50 Day Range

MA: $21.06
Low: $12.00
High: $31.93

2 Week Range

Now: $19.47
Low: $1.82
High: $33.89

Volume

1,900,299 shs

Average Volume

3,599,758 shs

Market Capitalization

$14.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A